Contrasting CervoMed (CRVO) & Its Competitors

CervoMed (NASDAQ:CRVO) is one of 1,077 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its peers? We will compare CervoMed to related businesses based on the strength of its risk, valuation, profitability, institutional ownership, earnings, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for CervoMed and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CervoMed	1	1	5	2	2.89
CervoMed Competitors	8782	22791	51148	1423	2.54

CervoMed presently has a consensus price target of $27.63, suggesting a potential upside of 226.15%. As a group, “Pharmaceutical preparations” companies have a potential upside of 227.36%. Given CervoMed’s peers higher possible upside, analysts clearly believe CervoMed has less favorable growth aspects than its peers.

Profitability

This table compares CervoMed and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CervoMed	-118.68%	-44.11%	-39.81%
CervoMed Competitors	-3,399.87%	-235.11%	-32.77%

Risk & Volatility

CervoMed has a beta of -0.23, indicating that its share price is 123% less volatile than the S&P 500. Comparatively, CervoMed’s peers have a beta of 4.27, indicating that their average share price is 327% more volatile than the S&P 500.

Valuation & Earnings

This table compares CervoMed and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
CervoMed	$7.14 million	-$2.17 million	-3.89
CervoMed Competitors	$9.91 billion	$136.15 million	-5.25

CervoMed’s peers have higher revenue and earnings than CervoMed. CervoMed is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Insider & Institutional Ownership

25.1% of CervoMed shares are held by institutional investors. Comparatively, 43.9% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 35.4% of CervoMed shares are held by company insiders. Comparatively, 13.5% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

CervoMed peers beat CervoMed on 7 of the 13 factors compared.

CervoMed Company Profile

CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.